IBMX

Alias: IBMX;3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine
Cat No.:V4097 Purity: ≥98%
IBMX is anonspecific, broad-spectrum, competitive inhibitor of phosphodiesterase (PDE) inhibitor, withIC50s of 6.5, 26.3 and 31.7 μM forPDE3,PDE4andPDE5, respectively.
IBMX Chemical Structure CAS No.: 28822-58-4
Product category: Phosphodiesterase(PDE)
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
25mg
50mg
100mg
250mg
500mg
1g
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

IBMX is a nonspecific, broad-spectrum, competitive inhibitor of phosphodiesterase (PDE) inhibitor, with IC50s of 6.5, 26.3 and 31.7 μM for PDE3, PDE4 and PDE5, respectively. It enhances the intracellular cAMP levels and also acts as an adenosine (A1) receptor antagonist. IBMX raises intracellular cAMP, activates PKA, inhibits TNFα and leukotriene synthesis, and reduces inflammation and innate immunity. IBMX, a non-selective PDE inhibitor significantly decreases the liver glycogen storage (mg/g, IBMX 22±1.5 P<0.001). IBMX potentiates insulin release and in hepatocytes and adipocytes, they increase glycogenolysis and lipolysis. Pretreatment of CCDs (cortical collecting duct) with IBMX, a broad-spectrum PDE inhibitor, or cilostamide, a PDE3 inhibitor, abolished the stimulatory effect of ANG II on ROMK channels.

Biological Activity I Assay Protocols (From Reference)
ln Vitro
The most efficient concentrations for inducing airway relaxation were 100 μM for both KMUP-1 (a xanthine peptide inducer) and IBMX; there was no discernible variation in the activation of the induction response triggered by either compound [1]. Renal outer medulla K+ (ROMK) channels were activated (n=6, P<0.05) by IBMX (100 μM), while ANG II (n=6, P=NS) or cGMP could not further activate these channels. Notably, tubular cAMP content increased significantly to 1.43±0.35 pg/mm tubule length (n =14) after 20 minutes of sham-containing nutrient collecting ducts (CCDs) isolated from high K+ (HK)-fed scaffolds with IBMX (100 μM) compared to tubule length measured in vehicle-treated controls (0.61±0.13 pg/mm tubule length, n =12, P<0.05)[2].
ln Vivo
Liver glycogen reserves are considerably reduced by IBMX, a non-selective PDE (mg/g, IBMX 22±1.5 P<0.001). IBMX and mc5 were found to significantly increase cardiac signs (glucose, mg/dl, control=141±3, IBMX=210±17 P<0.001 and mc5=191±13 P<0.01) when compared to serum. In contrast, compounds from mc1, mc6, MCPIP, and Win 47203 did not significantly affect any of the subjects (control=141±3, mc1 160±7, mc6 175±9, MCPIP 179±8, and Win 47203 116±2 P>0.05). mc2 was not found to alter the umbilical cord scale (control=141±3 and mc2=145±5). When it comes to boosting cardiovascular core, IBMX is the most effective [3]. While apocynin and IBMX treatment did not significantly lower cold exposure in the right ventricle (RV), they did considerably minimize the cold-induced increase in systolic blood pressure (23.5 ± 1.8 and 24.2 ± 0.6 mmHg, respectively). The lumen diameter increases to 62.7 ± 4.2 and 59.5 ± 4.3 μM, respectively, while the thickness of the PA medial layer is 19.0 ± 0.9 and 16.9 ± 0.8 μM, respectively] [4].
References
[1]. Wu BN, et al. KMUP-1, a xanthine derivative, induces relaxation of guinea-pig isolated trachea: the role of the epithelium, cyclic nucleotides and K+ channels. Br J Pharmacol. 2004 Aug;142(7):1105-14
[2]. Wei Y, et al. Angiotensin II type 2 receptor regulates ROMK-like K+ channel activity in the renal cortical collecting duct during high dietary K+ adaptation. Am J Physiol Renal Physiol. 2014 Oct 1;307(7):F833-43
[3]. Hosseini A, et al. Differential metabolic effects of novel cilostamide analogs, methyl carbostiryl derivatives, on mouse and hyperglycemic rat. Iran J Basic Med Sci. 2012 Jul;15(4):916-25.
[4]. Crosswhite P, et al. Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension. Hypertension. 2013 Mar;61(3):585-92
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C10H14N4O2
Molecular Weight
222.25
CAS #
28822-58-4
SMILES
O=C(N1C)N(CC(C)C)C2=C(NC=N2)C1=O
Chemical Name
3-Isobutyl-1-methylxanthine
Synonyms
IBMX;3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO:≥ 40 mg/mL
Water:< 1mg/mL
Ethanol:N/A
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 4.4994 mL 22.4972 mL 44.9944 mL
5 mM 0.8999 mL 4.4994 mL 8.9989 mL
10 mM 0.4499 mL 2.2497 mL 4.4994 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Biological Data
  • IBMX

    The stimulatory effect of ANG II on ROMK channel activity in HK-fed rats is mediated by phosphodiesterases (PDEs).2014 Oct 1;307(7):F833-43
  • IBMX

    Total cAMP content in single CCDs of HK-fed rats is increased after IBMX treatment.2014 Oct 1;307(7):F833-43

Contact Us